Week In Review: China Leads Global Pharma Innovation, Says Thomson Reuters

CASI Pharma (NSDQ: CASI), a US-China biopharma, received CFDA approval to extend the US Phase II trial of its lead molecule (ENMD-2076) in fibrolamellar carcinoma into China (see story). CASI is already testing ENMD-2076 in three additional US-China Phase II trials for other indications. ENMD-2076 is an oral Aurora A/angiogenic kinase inhibitor that slows cell division and inhibits formation of new blood vessels. Headquartered in Maryland with a lab in Beijing, CASI in-licenses products for the China market, but the company is developing ENMD-2076 globally. 

Company News

AliHealth (HK: 0241), the online health service of Alibaba (NYSE: BABA), will offer an updated version of its drug tracking service this month (see story). The previous version was shut down in February. The new service will be voluntary, offer low-cost entry and provide free authentication for consumers. The previous version was mandatory for pharmas, who complained about the expense and about AliHealth's dual role as regulator and future competitor. As the operator of the system, AliHealth could monitor China drug sales, giving their planned online pharma proprietary information about sales trends. 

 

1 2 3
View single page >> |

Disclosure: None

How did you like this article? Let us know so we can better customize your reading experience.

Comments

Leave a comment to automatically be entered into our contest to win a free Echo Show.